Company profile: Microbia
1.1 - Company Overview
Company description
- Provider of industrial biotechnology, developing, producing, and commercializing fermentation-based specialty ingredients and biomaterials, including carotenoids, biopolymers, and other biomaterials; maintains a strategic alliance with Tate & Lyle Investments.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Microbia
Microbiome Insights
HQ: Canada
Website
- Description: Provider of end-to-end microbiome DNA sequencing services and state-of-the-art bioinformatic analysis. Offerings include 16S V4 amplicon sequencing for taxonomic profiling, shotgun metagenomic sequencing for species-level and functional insights, short-chain fatty acid analysis in stool, qPCR for absolute abundance, and comprehensive bioinformatics processing and reporting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microbiome Insights company profile →
LevitasBio
HQ: United States
Website
- Description: Provider of label-free cellular analysis, isolation, and enrichment solutions using magnetic levitation. Offers LeviCell EOS (simultaneous processing of up to four samples) and LeviCell 1.0 for non-damaging examination and delivery of biological signatures, LeviSelect kits for lysis-free RBC and CD45+ depletion, and LeviMetrics AI software for sample characterization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LevitasBio company profile →
Fujifilm Cellular Dynamics
HQ: United States
Website
- Description: Provider of human induced pluripotent stem cell (iPSC)-derived cells and media for disease and preclinical research, including iCell GABANeurons, DopaNeurons, GlutaNeurons, and Microglia for drug discovery, neurological research, and neurotoxicity testing. Offers iPSCs and custom iPSCs/iCell products (MyCell), plus CDMO services for contract development and cGMP manufacture of clinical-grade human cells in industrial quantities to precise specifications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fujifilm Cellular Dynamics company profile →
Prism Pharma
HQ: United States
Website
- Description: Provider of cardiovascular injectable products for acute care, developing and commercializing therapies in the United States, including NEXTERONE, an antiarrhythmic injectable amiodarone, and PM103, an intravenous clopidogrel bisulfate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prism Pharma company profile →
Sartorius
HQ: Germany
Website
- Description: Provider of laboratory and process technologies and equipment for biopharmaceutical production and laboratory environments, offering bioprocess solutions including filtration, fermentation, and purification technologies, and lab products and services with instruments and consumables for research and quality control, helping develop and manufacture biotech medicines reliably, quickly, and economically.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sartorius company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Microbia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Microbia
2.2 - Growth funds investing in similar companies to Microbia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Microbia
4.2 - Public trading comparable groups for Microbia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →